Getting overwhelmed by the news is an everyday struggle for those wishing to stay in touch with the latest news. Our newsletter should make it easier for those interested in pharmacovigilance regulations, advancement in the relevant use of artificial intelligence, and personal growth. Approaching with care, the same as we provide PV services, we thoughtfully pick articles every month to keep you updated.
Commure Chief Strategy Officer Ian Shakil discusses the evolution of voice-enabled charting, and explains how Commure's acquisition of his scribe automation company, Augmedix, can help expand the technology's impact across healthcare.
This systematic review made it possible to identify a considerable number of indicators. Many of them aim to evaluate different aspects of PV activities that can be valuable from a public health and health system perspective. Therefore, we propose a new classification and a set of indicators useful for health services.
Finding effective treatment for patients with rare diseases can be very difficult. Since the EU orphan regulations entered into force in 2000, it has played a central role in facilitating the development and authorisation of medicines for rare diseases. And much more...
Finding effective treatment for patients with rare diseases can be very difficult. Since the EU orphan regulations entered into force in 2000, it has played a central role in facilitating the development and authorisation of medicines for rare diseases.
European Medicines Agency’s data protection notice regarding personal data processing in the Clinical Trials Information System (CTIS)
Clinical Trials Regulation becomes fully applicable
Commure Chief Strategy Officer Ian Shakil discusses the evolution of voice-enabled charting, and explains how Commure's acquisition of his scribe automation company, Augmedix, can help expand the technology's impact across healthcare.
Buzzworthy developments of the past few weeks.
Valerie Reich, vice president of healthcare strategy at Hero Digital, looks ahead to how those factors and patients understanding the predictive and personalization powers of health data will change healthcare this year.
This systematic review made it possible to identify a considerable number of indicators. Many of them aim to evaluate different aspects of PV activities that can be valuable from a public health and health system perspective. Therefore, we propose a new classification and a set of indicators useful for health services.
If Fierce Pharma Marketing’s annual list of the top 10 biggest potential drug launches of the coming year is any indication, biopharma may soon be in for a blockbuster boom. All together, the 10 meds that made the 2025 list stand to generate a whopping $29 billion in annual sales by the end of the decade.
Drug-induced liver injury (DILI) remains an active field of clinical research and investigation with more than 4700 publications appearing in 2023 relating to hepatotoxicity of all causes and injury patterns. As in years past, we have attempted to identify and summarize highlights and controversies from the past year’s literature.
25-27 March 2025
04-07 March 2025
24-28 February 2025 - 14:00 - 18:30
These are the trainings that NextPV representatives will execute in this and the upcoming month.
Pictures used in this newsletter were generated by AI.